{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:33:34Z","timestamp":1792794814724,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HUTCHMED","id":[{"id":"https:\/\/ror.org\/00wnvbd12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fruquintinib is a highly selective, oral inhibitor of all 3 VEGF receptors. The global, randomized, double-blind phase 3 FRESCO-2 trial (NCT04322539) met its primary endpoint demonstrating significantly improved overall survival in patients with refractory metastatic colorectal cancer (mCRC) who received fruquintinib plus best supportive care (BSC) versus placebo plus BSC. Here we report detailed safety data from FRESCO-2 including an analysis of treatment-related adverse events of special interest (AESIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Patients with mCRC eligible for FRESCO-2 had received all standard chemotherapies and prior anti-VEGF and anti-EGFR therapies if indicated, and displayed progression on, or intolerance to, TAS-102 and\/or regorafenib. Prespecified AESIs based on VEGFR tyrosine kinase inhibitor drug classes were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incidences of treatment-related AESIs were 64.9% with fruquintinib\u2005+\u2005BSC versus 23.0% with placebo\u2005+\u2005BSC. The most frequent all-grade treatment-related AESIs for fruquintinib were hypertension (28.9%; grade \u22653 10.7%), palmar-plantar erythrodysesthesia syndrome\/hand-foot skin reaction (PPE 18.6%; grade \u22653 6.1%), and hypothyroidism (15.6%; grade \u22653 0.4%). Dose reductions due to treatment-related AESIs were reported in 10.3% of patients who received fruquintinib\u2005+\u2005BSC versus 0.4% with placebo\u2005+\u2005BSC. The most common treatment-related AESIs resulting in dose reduction for fruquintinib were PPE syndrome (5.0%), hypertension (2.9%), and proteinuria (1.3%). Overall, 5.9% versus 0.9% had treatment-related AESIs resulting in study drug discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fruquintinib\u2005+\u2005BSC demonstrated a predictable and manageable safety profile in pretreated patients with mCRC and is a novel oral treatment option that prolongs survival and enriches the continuum of care in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae360","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T07:36:48Z","timestamp":1734680208000},"source":"Crossref","is-referenced-by-count":16,"title":["Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-0612","authenticated-orcid":false,"given":"Cathy","family":"Eng","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center , Nashville, TN 37232 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9744","authenticated-orcid":false,"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua , Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-397X","authenticated-orcid":false,"given":"Rocio","family":"Garcia-Carbonero","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Universitario 12 de Octubre, Facultad de Medicina, Universidad Complutense de Madrid , Madrid 28041 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"Elena","family":"Elez","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Institute of Oncology (VHIO) , Barcelona 08035 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East , Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Sobrero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Azienda Ospedaliera San Martino , Genoa 16132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garcia-Alfonso","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Universitario Gregorio Mara\u00f1\u00f3n , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Kocsis","sequence":"additional","affiliation":[{"name":"Department of Oncoradiology, B\u00e1cs-Kiskun Megyei Oktat\u00f3k\u00f3rh\u00e1z , Kecskem\u00e9t 6000 ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Cubillo","family":"Gracian","sequence":"additional","affiliation":[{"name":"Medical Oncology, HM Universitario Sanchinarro Centro Integral Oncol\u00f3gico Clara Campal , Madrid 28050 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, Universit\u00e0 degli Studi di Milano , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University , Suita 565-0871 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Randrian","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology Department, CHU de Poitiers, F-86000 Poitiers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Tomasek","sequence":"additional","affiliation":[{"name":"Department of Complex Oncology Care, Masaryk Memorial Cancer Institute , Brno 60200 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Chong","sequence":"additional","affiliation":[{"name":"Olivia Newton John Cancer & Wellness Centre, Austin Hospital , Heidelberg, VIC 3084 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yang","sequence":"additional","affiliation":[{"name":"HUTCHMED International Corporation. , Florham Park, NJ 07932 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Guevara","sequence":"additional","affiliation":[{"name":"HUTCHMED International Corporation. , Florham Park, NJ 07932 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Schelman","sequence":"additional","affiliation":[{"name":"HUTCHMED International Corporation. , Florham Park, NJ 07932 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajash","family":"Pallai","sequence":"additional","affiliation":[{"name":"HUTCHMED International Corporation. , Florham Park, NJ 07932 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Institute of Oncology (VHIO) , Barcelona 08035 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"2025033118434713600_CIT0001","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025033118434713600_CIT0002","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025033118434713600_CIT0003","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"2025033118434713600_CIT0004","author":"American Cancer Society","journal-title":"Survival rates for colorectal cancer 2023"},{"key":"2025033118434713600_CIT0005","first-page":"1","article-title":"The mechanism of action of regorafenib in colorectal cancer: a guide for the community physician","volume":"12","author":"Grothey","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"2025033118434713600_CIT0006","doi-asserted-by":"publisher","first-page":"170","DOI":"10.21037\/jgo.2017.06.10","article-title":"Immunotherapy in colorectal cancer: for the select few or all","volume":"9","author":"Arora","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"2025033118434713600_CIT0007","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2025033118434713600_CIT0008","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11864-015-0333-9","article-title":"Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer","volume":"16","author":"Papadimitriou","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"2025033118434713600_CIT0009","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025033118434713600_CIT0010","doi-asserted-by":"publisher","first-page":"888181","DOI":"10.3389\/fonc.2022.888181","article-title":"Microsatellite instability and metastatic colorectal cancer\u2014a clinical perspective","volume":"12","author":"Buchler","year":"2022","journal-title":"Front Oncol"},{"key":"2025033118434713600_CIT0011","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.3390\/ijms22147717","article-title":"Evidence-based second-line treatment in RAS wild-type\/mutated metastatic colorectal cancer in the precision medicine era","volume":"22","author":"Giordano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025033118434713600_CIT0012","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349561","article-title":"The evolving treatment landscape in BRAF-V600E-mutated metastatic colorectal cancer","volume":"42","author":"Tabernero","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025033118434713600_CIT0013","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"2025033118434713600_CIT0014","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"2025033118434713600_CIT0015","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2025033118434713600_CIT0016","author":"LONSURF (trifluridine and tipiracil) Prescribing Information, Taiho Pharmaceutical, Inc","year":"2023"},{"key":"2025033118434713600_CIT0017","author":"LONSURF (trifluridine and tipiracil) EU Summary of Product Characteristics, Taiho Pharmaceutical, Inc"},{"key":"2025033118434713600_CIT0018","author":"STIVARGA (regorafenib) Prescribing Information, Bayer, Inc","year":"2017"},{"key":"2025033118434713600_CIT0019","author":"STIVARGA (regorafenib) EU Summary of Product Characteristics, Bayer Inc"},{"key":"2025033118434713600_CIT0020","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.2217\/fon-2021-0202","article-title":"FRESCO-2: a global phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer","volume":"17","author":"Dasari","year":"2021","journal-title":"Future Oncol"},{"key":"2025033118434713600_CIT0021","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"2025033118434713600_CIT0022","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00280-016-3069-8","article-title":"A phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors","volume":"78","author":"Cao","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025033118434713600_CIT0023","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.2147\/CMAR.S215533","article-title":"Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2025033118434713600_CIT0024","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"2025033118434713600_CIT0025","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"2025033118434713600_CIT0026","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/jco.2023.41.4_suppl.67","article-title":"Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study","volume":"41","author":"Sobrero","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025033118434713600_CIT0027","year":"2023"},{"key":"2025033118434713600_CIT0028","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2025033118434713600_CIT0029","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1007\/s12325-020-01477-w","article-title":"Safety profile and adverse events of special interest for fruquintinib in Chinese patients with previously treated metastatic colorectal cancer: analysis of the phase 3 FRESCO trial","volume":"37","author":"Li","year":"2020","journal-title":"Adv Ther"},{"key":"2025033118434713600_CIT0030","author":"FRUZAQLA\u2122 (fruquintinib) summary of product characteristics"},{"key":"2025033118434713600_CIT0031","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"2025033118434713600_CIT0032","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"2025033118434713600_CIT0033","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"key":"2025033118434713600_CIT0034","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/1440-1681.12935","article-title":"Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis","volume":"45","author":"Zhu","year":"2018","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2025033118434713600_CIT0035","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"2025033118434713600_CIT0036","doi-asserted-by":"publisher","first-page":"84102","DOI":"10.18632\/oncotarget.21106","article-title":"Incidence and risk of regorafenib-induced hepatotoxicity","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"2025033118434713600_CIT0037","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1634\/theoncologist.2018-0072","article-title":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study","volume":"24","author":"Van Cutsem","year":"2019","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae360\/62820301\/oyae360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae360\/62820301\/oyae360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T18:23:17Z","timestamp":1743445397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae360\/8101338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae360","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyae360"}}